Cala Health

Executive Summary

Cala Health is a private digital health and neuroscience company specializing in non-invasive wearable neuromodulation therapies for chronic conditions. Its flagship product, the Cala kIQ System, is FDA-cleared and physician-prescribed, delivering Transcutaneous Afferent Patterned Stimulation (TAPS) therapy to reduce action hand tremor in patients with Essential Tremor and Parkinson's disease. The device offers on-demand therapy with integrated patient data tracking, positioning the company at the forefront of wearable neurostimulation. With a focus on chronic neurological disorders, Cala Health addresses a significant unmet need for non-pharmacological, non-invasive treatment options, particularly among patients who are refractory to or intolerant of medications. The company's technology leverages a deep understanding of neural circuitry to provide personalized, data-driven therapy, enhancing patient outcomes and quality of life. As a private entity, Cala Health has the agility to innovate and expand its pipeline, though financial details and stage of development remain undisclosed.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance Expansion for Additional Indications (e.g., migraine or chronic pain)60% success
• Q2 2026Publication of Phase III Clinical Trial Results in a Major Neurology Journal75% success
• Q4 2026Strategic Partnership or Licensing Deal with a Large Pharmaceutical or Medical Device Company50% success